Rocket Lab's Neutron delay looks minor because its cadence should scale much faster than Terran-R's in the long run, even if Terran-R flies first. A forward-dome manufacturing issue moved Neutron's first flight to 2027; Q2 now sounds more likely than the expected Q1. The delay is disappointing, but Electron reached 100 launches faster than Falcon 9, and Iridium does not need Neutron soon. Peter Beck's transparency is appreciated; management may have waited for a solution despite bad timing. … Show more

Rocket Lab's Neutron delay looks like a manufacturing issue, not a flawed design. Rocket Lab says it identified and mitigated dome voids, but this second setback delays launch revenue; first flight could slip to mid-2027 or later if testing finds more issues. Space Systems is about 81% of revenue and backlog is around $2.4B, sustaining the business as Neutron develops. Rocket Lab could still become a megacap over the next decade. x.com 

Rocket Lab's delayed Neutron first flight pushes out a key part of its planned launch capacity. Flight one has moved to 2027, at least 1.5 years later than the previously indicated timing; the lack of clearer guidance is frustrating. The stock could fall 50% if it breaks key support, though that downside is conditional. x.com  x.com  x.com 

Rocket Lab's existing Space Systems business makes Neutron upside optionality rather than the whole investment case. Space Systems supplied $189.5M, about 81% of Q2's record $234M revenue, alongside Electron launches, defense work, satellite manufacturing and components. Delaying Neutron's first launch to 2027 hurts a major catalyst and raises execution questions, but rushing a rocket failure would be costlier. x.com 

Rocket Lab's Electron performance supports the case that it can scale Neutron faster than Terran-R, MLV and Stoke once it flies, as it has shown before. Retail patience with Neutron timelines is wearing thin, so Q3 earnings need good news, such as Archimedes engine qualification or the Stage 1 tank passing hydro and cryo tests; without either, investors will understandably be unhappy. x.com 

Repeated Neutron delays undermine the premium on Rocket Lab stock when execution keeps slipping. The company does not live or die by Neutron, but 50x sales was unjustified; even at 26x 2027 sales, a legitimate price suggests another 50% decline. x.com  x.com 

Rocket Lab's Neutron delay adds litigation risk despite continued support for the stock. Spaceflight Now reports a forward-dome manufacturing defect has pushed the debut into 2027, at the worst possible time. Expect a lawsuit with real merit; if recalled correctly, management said Neutron would be ready in mid-2025. x.com 

Rocket Lab's bounce has room to run to $65 after buyers returned following shipment of Neutron's second stage to its Virginia launch site. A break above $65 before November 9 results remains the real test. x.com 

Rocket Lab's Neutron delay could drag public space stocks down because the space basket usually trades together. Rocket Lab is likely to pull AST SpaceMobile down with it, especially in a bad market. The delay also pushes back a possible AST launch on Neutron, though that launch was not expected and the news is not necessarily bad for AST directly. x.com  x.com  x.com 

Rocket Lab's growing Space Systems business positions it to provide more than launches for the space economy. It generated $189.5M in Q2, 81% of revenue; if its pending Iridium acquisition closes, it would gain a global satellite communications network. At about $51, this is one of the most compelling long-term opportunities in the space sector over 3-5 years, provided it keeps executing. Neutron's launch has slipped to 2027, and execution risks remain. x.com  x.com  x.com